Vanguard Group Inc. Buys 133,738 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Vanguard Group Inc. lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,899,063 shares of the company's stock after acquiring an additional 133,738 shares during the quarter. Vanguard Group Inc. owned approximately 5.30% of Xeris Biopharma worth $26,778,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Wellington Management Group LLP increased its holdings in shares of Xeris Biopharma by 11.7% in the third quarter. Wellington Management Group LLP now owns 471,644 shares of the company's stock valued at $1,344,000 after purchasing an additional 49,535 shares during the last quarter. Barclays PLC boosted its holdings in shares of Xeris Biopharma by 87.8% during the 3rd quarter. Barclays PLC now owns 324,472 shares of the company's stock worth $925,000 after buying an additional 151,685 shares during the period. Geode Capital Management LLC grew its stake in Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after buying an additional 93,091 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Xeris Biopharma by 30.3% in the 3rd quarter. Principal Financial Group Inc. now owns 102,469 shares of the company's stock valued at $292,000 after acquiring an additional 23,843 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Xeris Biopharma by 20.8% during the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company's stock worth $1,117,000 after acquiring an additional 67,557 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XERS. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. Jefferies Financial Group reiterated a "buy" rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $6.10.

Xeris Biopharma Price Performance

XERS traded up $0.03 on Friday, hitting $4.11. 1,906,347 shares of the stock were exchanged, compared to its average volume of 1,862,277. The firm has a market capitalization of $632.69 million, a price-to-earnings ratio of -9.13 and a beta of 1.37. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $6.07. The business has a 50-day moving average of $4.44 and a two-hundred day moving average of $3.70.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.56% of the stock is currently owned by insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.